Arix Bioscience

Arix Bioscience was a prominent London-based global venture capital company dedicated to investing in and building breakthrough biotechnology companies. Established with a focus on transforming innovative scientific research into commercial success, Arix aimed to bridge the gap between academic discovery and patient impact. The firm typically targeted companies developing novel therapeutics across high-need areas such as oncology, immunology, gene therapy, and rare diseases. Their investment strategy involved not only providing capital but also offering significant operational and strategic support to their portfolio companies, often taking substantial equity stakes and playing an active role in their development.

The firm's approach was characterized by its commitment to long-term value creation, often participating in multiple funding rounds from seed to late-stage. Arix Bioscience was known for deploying significant capital into its portfolio, with initial investments typically ranging from approximately $10 million to $50 million, depending on the stage and capital requirements of the venture. For instance, they led a $25 million Series A round for Artios Pharma, a DNA damage response company, demonstrating their capacity for substantial early-stage commitments. They also participated in larger syndicates, such as a $100 million Series B round for Autolus Therapeutics, a T-cell immunotherapy company, in which Arix was a founding investor.

Arix Bioscience built a diverse portfolio of promising biotech ventures, aiming to accelerate the development of life-changing medicines. However, the independent operations of Arix Bioscience concluded in July 2022 when the company was acquired by RTW Investments, LP, a leading New York-based investment firm specializing in the biopharmaceutical and medical technology sectors. Following the acquisition, Arix's portfolio and investment activities were integrated into RTW's broader investment platform, marking the end of Arix Bioscience as a standalone venture capital entity.